Astrazeneca (AZN) Competitors

$181.62 -3.34 (-1.81%)

Closing price 05/15/2026 03:59 PM Eastern

Extended Trading

$182.07 +0.45 (+0.25%)

As of 05/15/2026 07:44 PM Eastern

AZN vs. AMGN, BIIB, MRNA, NVAX, and ABBV

Should you buy Astrazeneca stock or one of its competitors? MarketBeat compares Astrazeneca with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Astrazeneca include Amgen (AMGN), Biogen (BIIB), Moderna (MRNA), Novavax (NVAX), and AbbVie (ABBV).

How does Astrazeneca compare to Amgen?

Amgen (NASDAQ:AMGN) and Astrazeneca (NYSE:AZN) are related large-cap companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

In the previous week, Amgen had 23 more articles in the media than Astrazeneca. MarketBeat recorded 34 mentions for Amgen and 11 mentions for Astrazeneca. Amgen's average media sentiment score of 0.95 beat Astrazeneca's score of 0.45 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	19 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Amgen has a net margin of 20.96% compared to Astrazeneca's net margin of 17.19%. Amgen's return on equity of 137.41% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
Astrazeneca	17.19%	30.86%	12.68%

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.1%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.4%. Amgen pays out 70.1% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen presently has a consensus price target of $356.15, suggesting a potential upside of 9.15%. Astrazeneca has a consensus price target of $205.33, suggesting a potential upside of 13.06%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts clearly believe Astrazeneca is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Astrazeneca has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	4.79	$7.71B	$14.37	22.71
Astrazeneca	$58.74B	4.80	$10.23B	$6.66	27.27

Amgen has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 20.4% of Astrazeneca shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Amgen beats Astrazeneca on 13 of the 20 factors compared between the two stocks.

How does Astrazeneca compare to Biogen?

Astrazeneca (NYSE:AZN) and Biogen (NASDAQ:BIIB) are related large-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Astrazeneca presently has a consensus price target of $205.33, suggesting a potential upside of 13.06%. Biogen has a consensus price target of $215.62, suggesting a potential upside of 11.75%. Given Astrazeneca's stronger consensus rating and higher probable upside, equities research analysts clearly believe Astrazeneca is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Biogen	1 Sell rating(s)	13 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.52

Astrazeneca has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Biogen has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

In the previous week, Biogen had 39 more articles in the media than Astrazeneca. MarketBeat recorded 50 mentions for Biogen and 11 mentions for Astrazeneca. Biogen's average media sentiment score of 0.84 beat Astrazeneca's score of 0.45 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Biogen	19 Very Positive mention(s)	13 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Astrazeneca has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.80	$10.23B	$6.66	27.27
Biogen	$9.89B	2.88	$1.29B	$9.32	20.70

Astrazeneca has a net margin of 17.19% compared to Biogen's net margin of 13.81%. Astrazeneca's return on equity of 30.86% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
Biogen	13.81%	12.83%	8.01%

Summary

Astrazeneca beats Biogen on 10 of the 17 factors compared between the two stocks.

How does Astrazeneca compare to Moderna?

Astrazeneca (NYSE:AZN) and Moderna (NASDAQ:MRNA) are both large-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Astrazeneca has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.80	$10.23B	$6.66	27.27
Moderna	$1.94B	10.01	-$2.82B	-$8.15	N/A

Astrazeneca has a net margin of 17.19% compared to Moderna's net margin of -143.55%. Astrazeneca's return on equity of 30.86% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
Moderna	-143.55%	-26.64%	-19.32%

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Astrazeneca presently has a consensus price target of $205.33, suggesting a potential upside of 13.06%. Moderna has a consensus price target of $35.73, suggesting a potential downside of 27.13%. Given Astrazeneca's stronger consensus rating and higher probable upside, equities research analysts clearly believe Astrazeneca is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Astrazeneca has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

In the previous week, Moderna had 13 more articles in the media than Astrazeneca. MarketBeat recorded 24 mentions for Moderna and 11 mentions for Astrazeneca. Moderna's average media sentiment score of 0.74 beat Astrazeneca's score of 0.45 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Moderna	14 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Astrazeneca beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Astrazeneca compare to Novavax?

Astrazeneca (NYSE:AZN) and Novavax (NASDAQ:NVAX) are related companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.80	$10.23B	$6.66	27.27
Novavax	$596.34M	2.50	$440.30M	-$0.58	N/A

Astrazeneca has a net margin of 17.19% compared to Novavax's net margin of -14.73%. Astrazeneca's return on equity of 30.86% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
Novavax	-14.73%	-14.82%	1.23%

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 1.0% of Novavax shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Astrazeneca currently has a consensus price target of $205.33, suggesting a potential upside of 13.06%. Novavax has a consensus price target of $12.13, suggesting a potential upside of 33.83%. Given Novavax's higher possible upside, analysts clearly believe Novavax is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Astrazeneca has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Novavax has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market.

In the previous week, Novavax had 4 more articles in the media than Astrazeneca. MarketBeat recorded 15 mentions for Novavax and 11 mentions for Astrazeneca. Novavax's average media sentiment score of 0.80 beat Astrazeneca's score of 0.45 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Novavax	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Astrazeneca beats Novavax on 10 of the 16 factors compared between the two stocks.

How does Astrazeneca compare to AbbVie?

Astrazeneca (NYSE:AZN) and AbbVie (NYSE:ABBV) are related large-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Astrazeneca currently has a consensus price target of $205.33, suggesting a potential upside of 13.06%. AbbVie has a consensus price target of $253.43, suggesting a potential upside of 20.37%. Given AbbVie's stronger consensus rating and higher possible upside, analysts clearly believe AbbVie is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Astrazeneca has higher earnings, but lower revenue than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.80	$10.23B	$6.66	27.27
AbbVie	$61.16B	6.08	$4.23B	$2.03	103.71

Astrazeneca has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

In the previous week, AbbVie had 53 more articles in the media than Astrazeneca. MarketBeat recorded 64 mentions for AbbVie and 11 mentions for Astrazeneca. AbbVie's average media sentiment score of 1.11 beat Astrazeneca's score of 0.45 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
AbbVie	42 Very Positive mention(s)	12 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.4%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.3%. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Astrazeneca has a net margin of 17.19% compared to AbbVie's net margin of 5.79%. Astrazeneca's return on equity of 30.86% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
AbbVie	5.79%	-576.45%	13.39%

Summary

AbbVie beats Astrazeneca on 15 of the 20 factors compared between the two stocks.

Get Astrazeneca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZN vs. The Competition

Export

Metric	Astrazeneca	Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$286.86B	$2.94B	$4.74B	$22.98B
Dividend Yield	2.35%	15.19%	5.93%	4.09%
P/E Ratio	27.27	12.99	22.92	29.75
Price / Sales	4.80	1,854.96	121.17	14.03
Price / Cash	14.31	26.88	50.14	25.31
Price / Book	5.94	5.97	38.26	4.60
Net Income	$10.23B	-$42.19M	$113.55M	$1.07B
7 Day Performance	-0.60%	-0.70%	2.46%	-2.27%
1 Month Performance	-9.46%	1.47%	4.53%	-0.37%
1 Year Performance	31.97%	16.27%	16.78%	21.80%

Astrazeneca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZN Astrazeneca	3.9974 of 5 stars	$181.62 -1.8%	$205.33 +13.1%	+33.6%	$286.86B	$58.74B	27.27	96,100	Analyst Forecast
AMGN Amgen	4.0157 of 5 stars	$326.31 -3.0%	$356.15 +9.1%	+20.1%	$176.10B	$36.75B	22.71	31,500	Positive News Analyst Forecast
BIIB Biogen	3.6761 of 5 stars	$192.95 +0.8%	$215.62 +11.7%	+56.0%	$28.49B	$9.89B	20.70	7,500	Trending News Analyst Forecast
MRNA Moderna	1.5956 of 5 stars	$49.04 -2.0%	$35.73 -27.1%	+107.4%	$19.46B	$1.94B	N/A	4,700	Gap Down
NVAX Novavax	2.0957 of 5 stars	$9.06 -3.1%	$12.13 +33.8%	+44.0%	$1.49B	$1.12B	N/A	1,990	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AZN) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Astrazeneca (AZN) Competitors